Congress Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Congress Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-70,100	Closed	-$5.28M	–	382
2022 Q2	$5.28M	Buy	70,100 +308	+0.4%	+$13.7K	0.05%	215
2022 Q1	$1.87M	Buy	69,792 +35,147	+101%	+$1.18M	0.02%	287
2021 Q4	$1.65M	Buy	34,645 +10	+0%	+$447	0.01%	297
2021 Q3	$2.3M	Buy	+34,635	New	+$2.47M	0.02%	253

Congress Asset Management's TPTX Position: Q3 2022 in Review

Congress Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 70,100 shares — an estimated $5.28M sold.

Congress Asset Management first reported a position in TPTX in Q3 2021 and held it in 4 quarters. The position peaked at $5.28M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Congress Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Congress Asset Management sold 70,100 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $5.28M.
Congress Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
Congress Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $5.28M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Congress Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.